Arca
Skip to content
Tools
Tools

F11: Coagulation factor XI

Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. .

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on F11, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 2
  • Protein or peptide 1

Approved1

  • Human C1-esterase inhibitor

Phase 32

  • Abelacimab
  • Milvexian

Phase 21

  • Osocimab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Anthos Therapeutics, Inc.125%
    • IMMUNOe Research Centers125%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Coagulation factor XI inhibitor; the rest name their own mechanism.
    Human C1-esterase inhibitorApprovedIMMUNOe Research CentersProtein or peptideInhibitor5
    AbelacimabPhase 3Anthos Therapeutics, Inc.AntibodyInhibitor3
    MilvexianPhase 3Johnson & JohnsonSmall moleculeInhibitor2
    OsocimabPhase 2—AntibodyNegative allosteric modulatorCoagulation factor XI negative allosteric modulator0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
    Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious PathogensHuman C1-esterase inhibitorPhase 4RecruitingIMMUNOe Research CentersNov 12, 2026
    Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AnticoagulationAbelacimabPhase 3Not yet recruitingNovartis PharmaceuticalsJul 31, 2026
    Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)Human C1-esterase inhibitorPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)Apr 9, 2025
    Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksHuman C1-esterase inhibitorPhase 3RecruitingOctapharmaApr 12, 2024
    Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)Human C1-esterase inhibitorPhase 2RecruitingHaaglanden Medical CentreApr 11, 2024
    A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationMilvexianPhase 3Active, not recruitingJanssen Research & Development, LLCMar 7, 2023
    Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)AbelacimabPhase 3RecruitingAnthos Therapeutics, Inc.Feb 3, 2023
    A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEMilvexianPhase 3Active, not recruitingJanssen Research & Development, LLCJan 27, 2023
    A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaHuman C1-esterase inhibitorPhase 1 / Phase 2Active, not recruitingBioMarin PharmaceuticalNov 16, 2021
    Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial FibrillationAbelacimabPhase 2Active, not recruitingAnthos Therapeutics, Inc.Feb 16, 2021

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Factor XI deficiency0.85
    • Congenital factor XI deficiency0.77
    • Deep vein thrombosis0.59
    • Heart disorder0.55
    • Phlebitis0.55
    • Thrombophlebitis0.54
    • Cardiovascular disorder0.52
    • Pulmonary Infarction0.51

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2820, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P03951, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.